Back

High discontinuation rate of statins among PCSK9i users: a nationwide study from 2015-2023

30 August 2024 (11:09 - 11:21)
Organised by: Logo
Congress Presentation Part of: Lifestyle, obesity, and dyslipidaemia Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Ingrid Engebretsen

Oslo Economics, Oslo (Norway)

4 More presentations in this session

Presentation thumbnail
The impact of pre-myocardial infarction exercise frequency on prognosis in acute myocardial infarction patients
Doctor T. Gu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Revisiting the obesity paradox: lean body mass, fat mass, and mortality in patients with atrial fibrillation
Professor Y. Lu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Association between achieved cholesterol levels and the risk of major adverse cardiovascular events after acute coronary syndromes
Mr C. Follonier (Geneva, CH)
Abstract Slides Video
Presentation thumbnail
Comparing PCSK9 inhibitor prescription rates within high-risk populations: diabetes mellitus, multi-territory vascular disease, multivessel and recurrent coronary artery disease
Doctor W. He (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Lifestyle, obesity, and dyslipidaemia
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 11:09 CET
You may be interested in
thumbnail
Congress Session
Changing face of lipid-lowering therapy
thumbnail
Congress Session
Lifestyle, obesity, and dyslipidaemia
thumbnail
Congress Presentation
Resistance to lipid-lowering therapy with PCSK9 inhibitors: comparative efficacy and clinical implications

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources